Although an association between hepatitis C virus (HCV) infection and oropharyngeal cancers (OPCs) has been reported, to the authors' knowledge the clinical significance of this epidemiological finding remains unknown. Therefore, the authors analyzed the oncologic outcomes of HCV-infected patients with OPCs. METHODS: In this retrospective cohort study, all patients with OPCs who were seen at The University of Texas MD Anderson Cancer Center between January 2004 and December 2015 were reviewed. HCV infection was defined as detectable HCV RNA in the serum. Five-year overall survival and progression-free survival rates were compared between patients infected with HCV and those not infected. RESULTS: A total of 161 patients were examined. The majority of the patients were white (141 patients; 88%) and male (132 patients; 82%) and had TNM stage III or IV disease (147 patients; 91%). The OPC involved the tonsils (83 patients; 52%), base of the tongue (67patients; 42%), or the soft palate (11 patients; 7%). The median follow-up after an OPC diagnosis was 3 years (range, 1-13 years). HCV-infected patients (25 patients) and HCVuninfected patients (136 patients) were comparable with regard to smoking and alcohol status. In multivariate analysis, HCV was associated with increased cancer-specific mortality (hazard ratio, 2.15; 95% confidence interval, 1.08-6.85 [P 5.02]) and risk of OPC progression (hazard ratio, 5.42; 95% confidence interval, 2.64-11.14 [P 5.0008]) independent of age and cirrhosis status. Antivirals were administered after the diagnosis of OPC in 8 of the 25 HCV-infected patients (32%). HCV-infected patients who received antivirals were found to have better 5-year overall survival (70% vs 12%; P 5.005) and progression-free survival (72% vs 19%; P 5.005) compared with patients who did not. CONCLUSIONS: The early detection of HCV is important in patients with OPC because this infection may affect their oncologic outcomes. Cancer 2018;124:960-5.
INTRODUCTION
Hepatitis C virus (HCV) is a globally prevalent pathogen and a leading cause of morbidity and death. 1 HCV is carcinogenic and associated with the development of hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma (NHL). 2 In addition, HCV seropositivity or HCV infection appears to increase the risk of mortality from several cancers, including those of the rectum, liver, pancreas, lung, esophagus, thyroid, and prostate. [3] [4] [5] [6] Recently, we reported that chronic HCV infection is associated with head and neck cancers, particularly human papillomavirus (HPV)-positive oropharyngeal cancers (OPCs). 7 Additional studies from the United States 8 and Europe 9 have confirmed such findings but to our knowledge the clinical significance of these epidemiological observations remains unknown. Patients with OPC are a distinct group of individuals with specific treatment modalities. Therefore, we studied the impact of HCV infection on the oncologic outcomes of patients with OPC.
MATERIALS AND METHODS
In the current retrospective cohort study, the medical records of patients with OPC seen at The University of Texas MD Anderson Cancer Center from January 2004 to December 2015 were reviewed. Baseline assessments included standard clinical laboratory testing, smoking and alcohol history assessment, measurement of serum HCV RNA levels, and HCV genotype. Smoking-related information collected included smoking status (never, former, or current smoker). Former smokers were those who had quit at least 1 year before their cancer diagnosis. Alcohol-related information collected included drinking status (never, former, or current drinker). Former drinkers were those who had quit at least 1 year before their cancer diagnosis.
HCV RNA levels were measured by means of the cobas AmpliPrep/cobas TaqMan HCV test (versions 1.0 and 2.0; Roche Molecular Systems, Branchburg, New Jersey). Patients who tested positive for the HCV antibody (anti-HCV) with detectable HCV RNA were considered to be "HCVinfected," whereas those who tested negative for the antibody were considered to be "HCV-uninfected." Patients who tested positive for anti-HCV with HCV RNA that was either undetectable or never tested were excluded because such patients could have false-positive anti-HCV results or spontaneous viral clearance. Cirrhosis was diagnosed on the basis of liver biopsy or a combination of clinical findings (eg, ascites, encephalopathy, or jaundice) and radiologic findings (eg, hepatic nodularity) and serum biomarkers (Prometheus FIBROspect II; Prometheus Laboratories, San Diego, California). We compared 5-year overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) between HCV-infected and HCV-uninfected patients. OS was calculated from the date of cancer diagnosis to the time of death, last date of follow-up, or the completion of 5 years of follow-up, whichever came earlier. PFS was calculated from the date of cancer diagnosis to the date of disease progression, death, last date of follow-up, or the completion of 5 years of follow-up, whichever came earlier. DFS was calculated from the date of last treatment received to the date of disease recurrence, death, last date of follow-up, or the completion of 5 years of follow-up, whichever came earlier. DFS was calculated only for those patients who achieved complete remission after first-line treatment.
Only patients with OPC were studied because this is a more homogeneous group with standardized nonsurgical treatment, and surgical and pathologic variables were removed as potential confounders in the survival analyses. OPC progression was identified either clinically or radiologically. Follow-up began at the date of OPC diagnosis and ended at the date of death or last follow-up visit. The effect of antiviral treatment (AVT) (either interferon-based or interferon-free regimens) on the survival outcomes among HCV-infected patients with OPC was explored.
We extracted data regarding demographics, cigarette smoking status, and alcohol consumption at the time of the cancer diagnosis. The smoking-related information collected included smoking status (never, former, or current smoker) and the duration of smoking in pack-years (the number of cigarette packs smoked per day multiplied by the number of years smoking). Former smokers were those who had quit at least 1 year before the diagnosis of OPC. Alcohol-related information included drinking status (never, former, or current drinker). An OPC was considered to be HPV-positive if it was positive for p16 protein expression according to immunohistochemistry, as defined in pathology reports.
Statistical Analysis
Descriptive statistics were used to characterize the study population. Categorical variables were compared using the chi-square or Fisher exact tests. Continuous variables were compared using the Wilcoxon rank sum test. Survival probabilities in the patients with and without HCV infection were compared using a log-rank test. Multivariable Cox regression models were used to determine the association between HCV infection, risk of death, and disease progression after adjusting for potential confounders. In the final multivariable analysis, only OPC-specific mortality was analyzed. We did not analyze all-cause mortality because the differences in outcome between HCVinfected and HCV-uninfected patients could be due to uncontrolled confounding covariates.
Furthermore, to determine whether AVT affects the oncologic outcomes in HCV-infected patients, those individuals treated with AVT after their OPC diagnosis were compared with those who were not treated using a logrank test. P values < .05 were considered to be statistically significant.
RESULTS
We studied 178 patients with OPCs. Seventeen patients (10%) with positive anti-HCV antibody and anti-HCV antibody that was undetectable or never tested were excluded. Further analysis was performed in the remaining 161 patients, 25 of whom (16%) were infected with HCV and 136 of whom (84%) were uninfected. By definition, all 25 HCV-infected patients had anti-HCV and detectable HCV RNA. The median follow-up after an OPC diagnosis was 3 years (interquartile range [IQR], 1.8-4.7 years). The demographic, hepatic, virologic, and oncologic characteristics of the HCV-infected and HCV-uninfected patients are compared in Table 1 and Table 2 . Of the 161 patients, 86 (53%) were HPV positive, 22 patients (14%) were HPV negative, and 53 patients (33%) had unknown HPV status. HPV-related OPCs were found to be equally distributed among patients with and without HCV infection. Only 2 patients in the entire cohort (1%) were infected with the human immunodeficiency virus.
In univariate analysis, HCV-uninfected patients were found to have better 5-year OS and PFS rates compared with HCV-infected patients (26% vs 8% [P 5 .003] and 73% vs 48% [P 5 .0008], respectively). After first-line cancer treatment, 113 patients (70%) achieved complete remission. Nine of these patients were infected with HCV and 104 were uninfected. In these patients, the DFS rates were similar (77% in the HCV-uninfected vs 65% in the HCV-infected patients; P 5 .15). Multivariable Cox regression analysis demonstrated that HCV infection was associated with a 2-fold increase in the risk of death due to OPC (hazard ratio, 2.1; 95% confidence interval, 1.0-4.1) and a 3-fold increase in the risk of OPC progression at 5 years (hazard ratio, 3.1; 95% confidence interval, 1.5-6.4) independent of age and cirrhosis status ( Figs. 1 and 2 ).
AVT was administered after the diagnosis of OPC in 8 of the 25 HCV-infected patients (32%), with 6 of these patients receiving interferon-free AVT (4 patients received sofosbuvir/ledipasvir in a fixed-dose combination and 2 patients received sofosbuvir plus ribavirin). All 8 patients had sustained virologic responses 12 weeks after the end of treatment, and were regarded as cured of HCV infection. In univariate analysis, HCV-infected patients who had received treatment were found to have better 5-year OS (70% vs 12%; P 5 .005) and 5-year PFS (72% vs 19%; P 5 .005) rates compared with untreated patients. We observed no statistically significant differences in the DFS, but the percentage of patients treated with AVT who were free of disease at 5 years was higher than that of untreated patients (100% vs 57%; P 5 .33).
DISCUSSION
To our knowledge, this is the first study to date to analyze the clinical impact of chronic HCV infection on oncologic outcomes in patients with OPC. We found that HCV infection was associated with an increased risk of cancer-specific mortality and cancer progression independent of patient age and cirrhosis status. Head and neck cancer is the sixth most common type of cancer in the world. 10 OPCs comprise a distinct entity among head and neck cancers. In a large study performed by our group, we found that HCV infection was significantly associated with OPCs, 7 a finding that also was validated by others, 8, 9 but the oncologic significance of such an association was unclear.
HCV infection negatively affects the oncologic outcomes of patients with [11] [12] [13] or without HCV-associated malignancies.
14 For example, in patients with advanced HCC, underlying HCV infection was found to be associated with worse outcomes when compared with patients without HCV infection. 4 Another finding in patients with advanced HCC was that eradication of HCV before the era of sorafenib improved OS and postprogression survival. 13 In addition, HCV-infected patients with diffuse large B-cell NHL had worse 5-year OS compared with those who were not infected with HCV. 15 The results of the current study demonstrated that HCV infection leads to a poor cancer prognosis in patients with OPCs after adjusting for potential confounders. A previous study regarding the effect of HCV in patients with head and neck cancers did not find any significant impact on oncologic outcomes. However, that study included mainly patients with relatively early HCV infection, thereby precluding analysis of chronic implications. 16 The higher mortality observed in patients with HCVassociated malignancies such as HCC can be attributed to worsening liver function, particularly among those with decompensated cirrhosis. However, this is not applicable to patients with HCV-associated NHL, the majority of whom Figure 1 . Five-year cancer-specific mortality in hepatitis C virus (HCV)-infected and HCV-uninfected patients with oropharyngeal cancers. Shown are Kaplan-Meier estimates of cancerspecific mortality according to treatment group. Hazard ratios, 95% confidence intervals, and P values were calculated using a Cox regression model comparing HCV-infected patients (25 patients) and HCV-uninfected patients (136 patients) after adjustment for cirrhosis status (yes vs no), age at cancer diagnosis (>65 years vs < 65 years), and tumor stage (I, II vs III, and IV). have mild liver disease. 17 Our group and others have demonstrated that viral eradication after AVT improves the oncologic outcomes of patients with HCV-associated NHL, suggesting a direct effect of this carcinogenic virus on survival. 15, 18 There also is evidence of increased mortality among HCV-infected patients from non-liver-related deaths, including renal and cardiovascular deaths, most likely from chronic inflammation. 6, 19, 20 Sustained virologic response with interferon-free regimens is associated with a significant mortality benefit in such patients. 21 The current study included many HCV-infected patients who were seen before 2013, the year when more effective, less toxic, and better tolerated AVTs (interferon-free regimens) were introduced in the United States. Even in the general population, the previous standard treatment of HCV with interferon and ribavirin was given to only a minority of infected patients (<20%). 22 In the current study, the majority of the patients treated with AVT (6 of 8 patients) received interferon-free regimens, which are the most effective and safe therapies currently being used, even in patients with cancer. 23 Achievement of a sustained virological response has been associated with better overall survival and a reduced risk of extrahepatic manifestations. 24, 25 The current study had some limitations. First, we examined a single-institution cohort including a small number of HCV-infected patients. However, these patients all were proven cases of HCV infection (detectable HCV RNA), which may not be possible in population-based studies. Second, as in every retrospective study, there is a risk of confounding bias, which we addressed by performing multivariable analysis to control for independent predictors of survival outcomes. Third, smoking and alcohol history were defined at the time of OPC diagnosis and we were unable to control for potential cessation after diagnosis. Fourth, the majority of patients seen at The University of Texas MD Anderson Cancer Center have stage IV disease. As a result, the survival rates of the patients in the current study were lower independent of HCV infection status. Fifth, AVT was provided to a small group of patients and therefore the results should be interpreted with caution. Patients who were deemed to have better survival were more likely to receive AVT, illustrating a potential selection bias. Sixth, we did not collect information regarding all comorbidities (eg, obesity, diabetes), some of which could potentially increase mortality in the patients in the current study. 
